Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy.

ABSTRACT:

Background

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer that is characterized by its poor prognosis, rapid progression and development of drug resistance. Chemotherapy is a vital treatment option for most of PDAC patients. Stratification of PDAC patients, who would have a higher likelihood of responding to chemotherapy, could facilitate treatment selection and patient management.

Methods

A quantitative proteomic study was performed to characterize the protein profiles in the plasma of PDAC patients undergoing chemotherapy to determine if specific biomarkers could be used to predict likelihood of therapeutic response.

Results

By comparing the plasma proteome of the PDAC patients with positive therapeutic response and longer overall survival (Good-responde

SUBMITTER: Peng H 

PROVIDER: S-EPMC6636003 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature